Life Science REIT’s (LABS) “Buy” Rating Reaffirmed at Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Life Science REIT (LON:LABS) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a GBX 57 ($0.76) price target on the stock.

A number of other equities research analysts also recently issued reports on LABS. Jefferies Financial Group reduced their price objective on shares of Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a hold rating for the company in a research report on Friday, August 30th. Shore Capital reaffirmed a buy rating on shares of Life Science REIT in a report on Thursday, September 26th.

Life Science REIT Price Performance

Shares of LON LABS opened at GBX 39 ($0.52) on Thursday. Life Science REIT has a 1 year low of GBX 31.30 ($0.42) and a 1 year high of GBX 74.20 ($0.99). The stock has a market capitalization of £136.50 million, a P/E ratio of -650.00 and a beta of 0.08. The company has a 50-day moving average price of GBX 34.15 and a 200-day moving average price of GBX 35.86.

Life Science REIT Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, October 31st. Stockholders of record on Thursday, October 3rd will be given a dividend of GBX 1 ($0.01) per share. This represents a dividend yield of 3.11%. The ex-dividend date is Thursday, October 3rd. Life Science REIT’s dividend payout ratio is presently -3,333.33%.